{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-059147","form_type":"8-K","ticker":"RZLT","cik":"0001509261","company_name":"Rezolute, Inc.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.157780+00:00","generated_at":"2026-06-15T04:01:34.951857+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Rezolute Q3 FY2023 net loss $15.7M; cash $129.2M; Phase 3 for RZ358 on track for Q3 2023","bullets":["Net loss of $15.7M for Q3 FY2023, compared to $11.2M in same period last year.","Cash and equivalents $33.7M plus marketable debt securities $95.5M as of March 31, 2023.","R&D expenses rose to $14.2M from $8.7M, driven by clinical trial and manufacturing costs.","Company expects to commence Phase 3 study for RZ358 in Q3 calendar 2023; Phase 2 for RZ402 enrolling.","G&A expenses increased to $2.9M from $2.1M due to higher personnel and stock-based compensation."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-059147","json":"https://secwatch.observer/filing/0001104659-23-059147.json","markdown":"https://secwatch.observer/filing/0001104659-23-059147.md","text":"https://secwatch.observer/filing/0001104659-23-059147.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1509261/000110465923059147/0001104659-23-059147-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1509261/000110465923059147/tm2315328d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T04:01:34.951857+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9c3c90bb05af857ce4575dbf6d83023e4d034922","claim":"Rezolute, Inc. reported third quarter of fiscal 2023 ended March 31, 2023 results: net income $15.7 million.","evidence_excerpt":"Net loss was $15.7 million for the third quarter of fiscal 2023, compared to $11.2 million for the same period in fiscal 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1509261/000110465923059147/0001104659-23-059147-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter of fiscal 2023 ended March 31, 2023"},{"label":"Net income","value":"$15.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}